Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2018 | Gene-based treatments show positive outcomes in AML

Harry Erba • 12 Sep 2018
SOHO 2018
Leukemia CPX-351 Cytarabine Enasidenib Gemtuzumab ozogamicin Midostaurin
ALFA 0701

Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Harry Erba of Duke University, Durham, NC, brings light upon the tendency of the healthcare community to favour an immediate diagnosis for patients with acute myeloid leukemia (AML), despite this doing more harm than good to patients. Waiting for genetic results can be a lengthy process, yet Dr Erba presents a compelling argument using evidence from a recent trial held in France in which patients with FLT3 mutations in AML showed increased chance of survival when taking targeted therapy. Dr Erba highlights the benefits of gene targeted therapy in AML; supporting the need to stratify patients to different treatments.

More from Harry Erba

MRD as a surrogate endpoint in AML: challenges, ongoing studies, and the need to standardize assays
7:48
MRD as a surrogate endpoint in AML: challenges, ongoing studies, and the need to standardize assays
Harry Erba • 28 Feb 2026
iwAL 2025 highlights: resistance mechanisms in AML, novel targets, menin inhibitors & more
21:29
iwAL 2025 highlights: resistance mechanisms in AML, novel targets, menin inhibitors & more
Aditi Shastri et al. • 19 Sep 2025
The Phase III QuANTUM-Wild trial: quizartinib in newly diagnosed FLT3-ITD-negative AML
6:43
The Phase III QuANTUM-Wild trial: quizartinib in newly diagnosed FLT3-ITD-negative AML
Harry Erba • 12 Jun 2025
Updated results of KOMET-007: exploring ziftomenib with 7+3 in newly diagnosed NPM1m or KMT2Ar AML
6:33
Updated results of KOMET-007: exploring ziftomenib with 7+3 in newly diagnosed NPM1m or KMT2Ar AML
Harry Erba • 12 Jun 2025

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals